Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Eliaz Therapeutics
AddedFeb 16, 2024
UpdatedJun 18, 2026
Eliaz Therapeutics

Eliaz Therapeutics

Seed

Eliaz Therapeutics: Innovating cardiovascular disease treatment via targeted therapeutic apheresis.

HQ
Santa Rosa, CA, US
Founded
2015
Overview
Compare
Fundraising
Employees
Website

Eliaz Therapeutics, founded with a mission to innovate cardiovascular disease treatment, focuses on developing novel therapeutic approaches using targeted therapeutic apheresis to remove Galectin-3 from the body. Their core product, the X-GAL-3 device, aims to address cardiovascular and related diseases by reducing harmful levels of Galectin-3, a protein associated with fibrosis and inflammation. The company targets the cardiovascular disease market, with additional applications in acute kidney injury (AKI).

Notable affiliations include a collaboration with Terumo Blood Cell Technologies for the development and commercialization of their apheresis treatment. Eliaz Therapeutics has achieved significant milestones, including a $1.7 million award from the NIH for their X-GAL-3 apheresis large animal safety study. The company's innovative approach has the potential to significantly impact the treatment landscape for cardiovascular diseases and related conditions, offering new hope for patients worldwide.

Eliaz Therapeutics - Similar Companies

Elastrin Therapeutics logo

Elastrin Therapeutics

elastrin.com

Elgia Therapeutics logo

Elgia Therapeutics

Elutia logo

Elutia

elutia.com

Galvanize Therapeutics logo

Galvanize Therapeutics

galvanizetx.com

eLum Technologies logo

eLum Technologies

Gamma Therapeutics logo

Gamma Therapeutics

HDL Therapeutics logo

HDL Therapeutics

Elixir Medical logo

Elixir Medical

elixirmedical.com

Elex Biotech logo

Elex Biotech

Elcelyx Therapeutics logo

Elcelyx Therapeutics

EnClear Therapies logo

EnClear Therapies

Ezalife logo

Ezalife

ezalife.com

eXIthera Pharmaceuticals logo

eXIthera Pharmaceuticals

exithera.com

Alessa Therapeutics logo

Alessa Therapeutics

Elysium Therapeutics logo

Elysium Therapeutics

elysiumrx.com

Eliaz Therapeutics - Quick Facts

Who are Eliaz Therapeutics' competitors?

Companies similar to Eliaz Therapeutics include Elastrin Therapeutics, Elgia Therapeutics, Elutia and Galvanize Therapeutics.

When was Eliaz Therapeutics founded?

Eliaz Therapeutics was founded in 2015.

Where is Eliaz Therapeutics' headquarters located?

Eliaz Therapeutics' headquarters is located in Santa Rosa, CA, US.

When was Eliaz Therapeutics' last funding round?

Eliaz Therapeutics' most recent funding round was for $1.7M (USD) in June 2022.

How much has Eliaz Therapeutics raised to-date?

As of Jun 23, 2022, Eliaz Therapeutics has raised a total of $1.7M (USD).

How many employees does Eliaz Therapeutics have?

Eliaz Therapeutics has 5 employees as of Feb 5, 2024.

Eliaz Therapeutics - Classification

Industry
  • Hardware
Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Americas
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 8 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research